{
  "kind": "treatment",
  "slug": "quetiapine-er-seroquel-xr",
  "type": "medication",
  "name": "Quetiapine ER (Seroquel XR)",
  "summary": "Quetiapine ER (Seroquel XR) is an extended-release atypical antipsychotic used to treat schizophrenia, bipolar disorder, and as adjunctive therapy for major depressive disorder.",
  "description": "Quetiapine ER, marketed as Seroquel XR, is an atypical antipsychotic that works primarily by antagonizing dopamine D2 and serotonin 5-HT2A receptors, among other targets. The extended-release formulation allows for once-daily dosing, maintaining therapeutic plasma levels over 24 hours. It is approved for the treatment of schizophrenia, bipolar mania and depression, and as adjunctive therapy for major depressive disorder.",
  "category": "medications/atypical-antipsychotics",
  "tags": [
    "antipsychotic",
    "extended-release",
    "bipolar disorder",
    "schizophrenia",
    "MDD adjunct"
  ],
  "metadata": {
    "drug_classes": [
      "Atypical antipsychotic"
    ],
    "therapeutic_categories": [
      "Psychiatry",
      "Neurology"
    ],
    "mechanism_categories": [
      "Dopamine Blocker",
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription only",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Seroquel XR"
    ],
    "age_groups": [
      "Adult",
      "Adolescent (schizophrenia: ≥13 years)",
      "Adolescent (bipolar mania: ≥10 years)"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Behavioral health"
    ],
    "fda_approval_year": 2007
  },
  "clinical_metadata": {
    "primary_indications": [
      "Psychosis",
      "Bipolar",
      "Depression"
    ],
    "off_label_uses": [
      "Generalized anxiety disorder",
      "Insomnia (low dose)",
      "PTSD"
    ],
    "contraindications": [
      "Known hypersensitivity to quetiapine or any component",
      "Caution in severe hepatic impairment"
    ],
    "monitoring_required": [
      "Weight, BMI",
      "Fasting glucose and lipid profile",
      "Blood pressure",
      "Signs of extrapyramidal symptoms and tardive dyskinesia",
      "Signs of metabolic syndrome"
    ],
    "efficacy_rating": {
      "Schizophrenia": 4,
      "Bipolar mania": 4,
      "Bipolar depression": 4,
      "MDD adjunct": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "quetiapine ER",
      "Seroquel XR",
      "extended-release quetiapine"
    ],
    "synonyms": [
      "quetiapine fumarate ER"
    ],
    "common_misspellings": [
      "quetapine",
      "seroquell"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Treatment of schizophrenia in adults and adolescents",
        "Treatment of acute manic or mixed episodes associated with bipolar I disorder",
        "Treatment of bipolar depression",
        "Adjunctive therapy in major depressive disorder"
      ]
    },
    {
      "type": "mechanism",
      "text": "Quetiapine acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, contributing to its antipsychotic and mood-stabilizing effects. It also has antagonistic activity at histamine H1 and alpha-1 adrenergic receptors, leading to sedative and hypotensive effects."
    },
    {
      "type": "dosing",
      "adult": {
        "Schizophrenia": "300–800 mg once daily, starting at 300 mg and titrating as tolerated",
        "Bipolar mania": "400–800 mg once daily, titrated over several days",
        "Bipolar depression": "300 mg once daily at bedtime",
        "MDD adjunct": "150–300 mg once daily in the evening"
      },
      "pediatric": {
        "Schizophrenia (13–17 years)": "400–800 mg once daily",
        "Bipolar mania (10–17 years)": "400–600 mg once daily"
      }
    },
    {
      "type": "dosage_forms",
      "items": [
        "Extended-release tablets: 50 mg, 150 mg, 200 mg, 300 mg, 400 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset: Within several days for mood symptoms, 1–2 weeks for antipsychotic effects; Duration: 24 hours with XR formulation"
    },
    {
      "type": "adverse_effects",
      "common": [
        "somnolence",
        "dizziness",
        "dry mouth",
        "constipation",
        "weight gain"
      ],
      "less_common": [
        "orthostatic hypotension",
        "dyslipidemia",
        "hyperglycemia"
      ],
      "serious": [
        "neuroleptic malignant syndrome",
        "tardive dyskinesia",
        "severe metabolic effects",
        "QT prolongation"
      ]
    },
    {
      "type": "warnings",
      "other": [
        "Elderly patients with dementia-related psychosis have an increased risk of death",
        "Monitor metabolic parameters regularly",
        "Use caution in patients with cardiovascular disease"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "CYP3A4 inhibitors (e.g., ketoconazole)",
          "risk": "Increased quetiapine levels",
          "action": "Avoid or reduce dose"
        },
        {
          "with": "CYP3A4 inducers (e.g., phenytoin, rifampin)",
          "risk": "Reduced quetiapine levels",
          "action": "May require dose increase"
        },
        {
          "with": "CNS depressants",
          "risk": "Additive sedation",
          "action": "Use with caution"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Metabolic parameters",
        "Cardiac status (QT interval)",
        "Ophthalmologic exams periodically for cataract risk"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Category C; use only if potential benefit justifies potential risk",
      "lactation": "Excreted in breast milk; caution advised",
      "geriatrics": "Increased risk of hypotension and sedation; use lower starting doses"
    },
    {
      "type": "tapering",
      "text": "Gradual dose reduction over at least 1–2 weeks to minimize withdrawal symptoms such as insomnia, nausea, and return of psychotic or mood symptoms"
    },
    {
      "type": "clinical_notes",
      "items": [
        "XR formulation should be taken without food or with a light meal (≤300 calories) to avoid altered absorption",
        "Sedation can be beneficial for patients with comorbid insomnia",
        "May cause dose-related orthostatic hypotension—advise slow position changes"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "FDA Label - Seroquel XR",
          "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022047s042lbl.pdf"
        },
        {
          "label": "Drugs.com - Quetiapine",
          "url": "https://www.drugs.com/quetiapine.html"
        },
        {
          "label": "PubChem - Quetiapine",
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/quetiapine"
        }
      ]
    }
  ],
  "seo": {
    "title": "Quetiapine ER (Seroquel XR) - Uses, Dosing, Side Effects, and Safety",
    "description": "Quetiapine ER (Seroquel XR) is an extended-release atypical antipsychotic for schizophrenia, bipolar disorder, and MDD adjunct therapy. Learn about dosing, side effects, and precautions."
  }
}
